ORUKA THERAPEUTICS INC

Oruka Therapeutics insider buy signals confidence in its heart‑failure pipeline, hinting at a potential upside despite current volatility and high risk.

Arjun Agarwal’s recent 10b5‑1 sale of ORUKA shares shows routine portfolio rebalancing, not a distress signal, as the company’s convertible notes boost investor confidence.

Oruka Therapeutics insiders buy at $7.80 amid a $1.3B convertible note—signals confidence and a potential buying opportunity as the stock recovers.

Insider buys by Oruka’s CMO signal confidence in its cardiovascular pipeline, hinting at upside before the 2027 data release.

Oruka Therapeutics insider trades reveal cautious optimism as CMO Joana Goncalves buys and sells shares, underscoring exec confidence in the company’s heart‑failure pipeline and future value.

Oruka Therapeutics insider sale: General Counsel sells 51k shares via Rule 10b5‑1 plan amid a 12.4% weekly rally, hinting at a potential pullback and urging investors to monitor cash burn and future partnership plans.

Oruka Therapeutics insider buys: Joana Gonçalves buys shares at $6.84‑$7.80, signaling confidence in the company’s heart‑failure pipeline and potential upside.

Oruka Insider Trading Insight: Arjun’s Rule 10b5‑1 moves mix strategic liquidity with long‑term confidence, revealing a disciplined approach to the biotech’s growth.

Insider selling by Oruka director Carl Dambkowski under a Rule‑10b5‑1 plan shows confidence in the stock’s valuation, not a warning sign.

Oruka Therapeutics’ finance chief’s buy‑then‑sell insider moves hint at confidence in the biotech’s pipeline, offering investors a potential bullish signal amid recent price swings.